Xequel Bio To Present Corporate Overview and Clinical Trial Data at Eyecelerator® at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

– Presentation Will Highlight Positive Clinical Trial Data on iNexin™ for Treatment of Corneal Injury – – Xequel Launches New Corporate Website with Focus on Novel Peptide Platform for Ophthalmology, Dermatology and Pulmonology – Charleston, SC and Fort Worth, TX, September 27, 2022 – Xequel Bio, Inc., a clinical stage biopharmaceutical company developing ophthalmic and dermatologic therapeutics […]

Xequel Bio Expands Leadership Team With Appointments Of Dr. Michael J. Brubaker As Chief Scientific Officer And Tony C. Tipton As Chief Operating Officer

Seasoned Biopharma Executives Bring Significant Clinical Development and Commercial Expertise Charleston, SC and Fort Worth, TX, July 26, 2022 – Xequel Bio, Inc., a clinical stage biopharmaceutical company developing dermatologic and ophthalmic therapeutics utilizing its patented new chemical entity aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide), announced today the appointments of Michael J. Brubaker, Ph.D., as Chief […]

Xequel Bio Announces Positive Results From Phase 1b Study Of INexinTM, A Novel ACT1 Ophthalmic Solution

Excellent Safety and Tolerability Profile for iNexin™ for the Treatment of Corneal Injury Early Efficacy Signals Provide Rationale to Advance to Phase 2 Proprietary aCT1 Platform to Address Unmet Needs for Patients with Ophthalmic Diseases Charleston, SCand Fort Worth, TX, July 14, 2022 –Xequel Bio, Inc., a clinical stage biopharmaceutical company developing ophthalmic and dermatologic […]